Is It Too Late to Buy Pfizer Stock?
Anyone not following the market would probably think that Pfizer (NYSE: PFE) did well last year. With the publicity from a potentially pandemic-ending vaccine and agreements for hundreds of millions of doses, it would make sense if the stock was one of the best performers since the outbreak of the virus. But that's not how the market works. Despite being a vastly different company than a year ago, Pfizer stock sits almost exactly where it did at this time in 2020. That might make it the perfect time to pick up shares.
Image source: Getty Images.
Pfizer began 2020 having generated almost $52 billion in revenue in the previous year thanks to eight products with more than $1 billion in sales. The company had recently reorganized itself into three segments: biopharmaceuticals, off-patent group Upjohn, and consumer health. The realignment was just preparation for the massive transformation that would occur later, focusing the more than century-old blue chip on developing new or better therapies for the most pressing diseases facing humanity.
Source Fool.com